Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1586 Trials   77739 News 


«12...7891011121314151617...897898»
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Outcomes with CDK4/6 inhibitor in metastatic hormone receptor () -  Apr 23, 2025 - Abstract #ASCO2025ASCO_4028;    
    The OS and PFS reported are similar to real-world studies even though the complete remission rates and adverse events were lower than western data which could be attributed to difference in tumor biology. There is no difference in survival with use of CDKi in first line versus subsequent lines.
  • ||||||||||  ZL-1310 / ZAI Lab
    ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update. (Hall A - Posters and Exhibits; Poster Bd #: 356) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_3657;    
    P1
    ZL-1310 demonstrated a tolerable safety profile and promising antitumor activity in r/r ES-SCLC, including pts with brain metastases, pt with prior tarlatamab, and in the setting of low DLL3 expression. Updated data, including patients in the randomized Part 2 dose optimization, will be presented.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Regorafenib response prediction in metastatic colorectal cancer by a novel genomic and transcriptomic model. (Hall A - Posters and Exhibits; Poster Bd #: 450) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_3603;    
    This novel predictive model successfully identified and validated molecular features associated with Rego-response in CRC. The transcriptomic and genetic signature holds significant potential for improving personalized treatment strategies by identifying patients most likely to benefit from Rego and prevents unnecessary Rego-associated toxicities in non-responders.
  • ||||||||||  Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
    Discovery of potent degraders of pan-KRAS based on a novel KRAS binder. (Hall A - Posters and Exhibits; Poster Bd #: 428) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_3560;    
    The innovative linker elongation and branching, coupled with modifications of KRAS binder portion significantly contributed to potent pan-KRAS degraders, which demonstrate excellent pharmacokinetics and exhibit remarkable efficacy both in vitro and in vivo. The IND-enabling studies are being conducted and the regulatory IND filing will be completed in 2025.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: The MIRAGE trial. (Hall A - Posters and Exhibits; Poster Bd #: 141a) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_3479;    
    P2
    MIRAGE, initiated in September 2024, is an academic trial promoted by the Istituto Oncologico Veneto, IOV-IRCCS and will recruit patients across 15 neuro-oncology Centers in Italy with an estimated study duration of 18 months. MIRAGE is the first randomized phase 2 trial analyzing the role of a RTK inhibitor (regorafenib) in prolonging PFS in pts with grade 2-3 meningioma who are ineligible for further surgery and/or radiotherapy.
  • ||||||||||  Itovebi (inavolisib) / Roche
    Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy  (Hall B1) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_3418;    
    P1
    Clinical Trial Registration Number: NCT03006172 Background: INAVO, a highly potent and selective PI3K? inhibitor that also promotes degradation of mutated p110?, is approved by the FDA in combination with PALBO + fulvestrant (FULV) for PIK3CA-mutated, HR+, HER2
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Prospective cohort study of palbociclib in HR+/HER2- metastatic breast cancer in Japan. (Hall A - Posters and Exhibits; Poster Bd #: 35) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_3397;    
    Although the background of each cohort needs to be further investigated, the PFS2 result of Cohort B was excellent and the subsequent 3-year OS of this cohort was satisfactory. Based on these results, the use of PAL in the 2nd line setting may be clinically acceptable.
  • ||||||||||  BTI615 / Chengdu Brilliant Pharma
    Efficacy of BTI615 on malignant cells expansion and bone marrow fibrosis in a myelofibrosis mice model. (Hall A - Posters and Exhibits; Poster Bd #: 188) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_2867;    
    Given its effective suppression on hyperplasia of atypical megakaryocytes, inflammation, marrow fibrosis and the ultimate recovery of hematopoietic function via modulating TGF-? signaling, BTI615 has a great potential to be the next generation therapeutic approach for MF.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer
    Outcomes of Ph-like B-lineage acute lymphoblastic leukemia in the era of novel therapies. (Hall A - Posters and Exhibits; Poster Bd #: 151) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_2830;    
    Adding novel agents (InO, blin, venetoclax) to upfront regimens may improve outcomes. Future studies should focus on optimal first-line combinations and higher-risk groups such as KRAS-mutated Ph-like B-ALL.
  • ||||||||||  Prolia (denosumab) / Amgen
    Pilot study of an enhanced telehealth program for patients with prostate cancer. (Hall A - Posters and Exhibits; Poster Bd #: 413) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_2365;    
    Patients found ET for the management of prostate cancer on ADT to be feasible, acceptable, and appropriate, providing a more patient-centered and convenient alternative to traditional clinic-based care. Future studies will explore scalability and applicability across diverse patient populations and treatment regimens.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    CDK4/6 inhibitor toxicity in geriatric subgroups: Evidence from the FAERS database. (Hall A - Posters and Exhibits; Poster Bd #: 146) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_2132;    
    Our findings demonstrated that liver toxicity was lower across all geriatric age subgroups, and hematological toxicity was reduced only in 75-84 age group. There were no significant differences in GI toxicities among the age subgroups.
  • ||||||||||  Qinlock (ripretinib) / Ono Pharma, Stivarga (regorafenib) / Bayer
    Second-line treatment patterns and outcomes of advanced gastrointestinal stromal tumor: A real-world study. (Hall A - Posters and Exhibits; Poster Bd #: 9) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_2041;    
    P
    Our preliminary results suggest that ripretinib may offer superior clinical benefits for patients with primary KIT exon 11 mutations after failure of imatinib first line treatment. Its favorable safety profile and improved tumor response rate facilitated a higher rate of surgical intervention compared to sunitinib.
  • ||||||||||  Prolia (denosumab) / Amgen
    Use of low-value cancer treatments in Medicare Advantage versus traditional Medicare. (Hall A - Posters and Exhibits; Poster Bd #: 414) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_1885;    
    These reductions in low value services may prevent avoidable toxicity and lower treatment cost to the patient and health care system. Increased efforts are needed to identify approaches that MA plans use to reduce low-value cancer treatments, and explore ways to promote those approaches in both MA and TM.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Impact of standard vs reduced dosing of sotorasib on efficacy and toxicity in KRAS G12C (Hall A - Posters and Exhibits; Poster Bd #: 73) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_1790;    
    No significant PFS benefit was observed with starting at 960 mg dose, highlighting the need to optimize dosing strategies that balance efficacy with tolerability. Future studies should include subgroup analyses of efficacy and tolerability for dose reductions to guide optimal dosing regimens, aligning with initiatives like the FDA's Project Optimus to improve patient outcomes.